![Denis Bedoret](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Denis Bedoret
Chief Executive Officer at ImCyse SA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Marie Gérard | F | - |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 9 years |
Stefan Braam | M | - |
Ncardia Holding SA
![]() Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | 9 years |
Hugues Bultot | M | 58 |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | 4 years |
Christina Franssen | M | - |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 years |
José Fernandez Castillo | M | - |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | 4 years |
Hugues Wallemacq | M | - |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 4 years |
Geoffrey Glass | M | - |
Ncardia Holding SA
![]() Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | 3 years |
Christine Franssen | F | - |
Ncardia Holding SA
![]() Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | 3 years |
Christel Dewitte | F | - |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | - |
Christian Borgniet | M | - |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | - |
Stijn van Rompay | M | 48 |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 12 years |
Thibault Jonckheere | M | - |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | - |
Thomas Taapken | M | 59 |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 years |
Jean-Marc Legrand | M | - |
Exothera SA
![]() Exothera SA Chemicals: SpecialtyProcess Industries Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere. | 4 years |
Vincent Brichard | M | - |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | - |
Jason Conner | M | - |
Ncardia Holding SA
![]() Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | 3 years |
Alain Parthoens | M | 64 |
Ncardia Holding SA
![]() Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | 3 years |
Stefan Yee | M | 62 |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 5 years |
Nicholas O'Leary | M | - |
Ncardia Holding SA
![]() Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jörg Neermann | M | 57 |
ImCyse SA
![]() ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 20 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Denis Bedoret
- Personal Network